Annual Report Reveals Going Concern Doubt, Material Weaknesses, and Recent Change in Control

summarizeSummary

Catalyst Crew Technologies' annual report for 2025 reveals substantial doubt about its ability to continue as a going concern, material weaknesses in internal controls, and details a recent change in control with new leadership and a strategic shift towards healthcare analytics.

check_boxKey Events

• Going Concern Warning Issued

  The independent auditor expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, with management acknowledging dependence on additional financing.

• Material Weaknesses in Internal Controls Identified

  Management concluded that internal controls over financial reporting were ineffective as of December 31, 2025, citing a lack of segregation of duties and limited financial resources to hire additional qualified personnel.

• Change in Control and New Leadership Confirmed

  Kevin Rodan Levy acquired a controlling stake (71.1%) in February 2026, leading to the resignation of previous executive officers and directors, and his appointment as CEO, President, CFO, Secretary, and Treasurer. Carlos Peña was subsequently appointed CFO in March 2026.

• Strategic Shift to Healthcare Analytics and International Expansion

  The company acquired AI-enabled healthcare analytics assets from Dr. Levy and a Venezuelan subsidiary, signaling a new strategic direction alongside its existing facial recognition technology development.

auto_awesomeAnalysis

This annual report highlights significant financial distress and operational challenges. The 'going concern' warning from the auditor, coupled with management's disclosure of ineffective internal controls due to limited resources, indicates a precarious financial position. While a change in control and new leadership, including CEO Kevin Rodan Levy, occurred recently and were previously disclosed in 8-Ks, this 10-K provides the full financial context of these events and the company's ongoing reliance on external financing. The strategic shift into healthcare analytics and the acquisition of a Venezuelan subsidiary under the new leadership represent a significant pivot, but the company remains in a development stage with no revenue, underscoring high operational risk.